In 2017, Domain Therapeutics and Pfizer signed a collaboration agreement to accelerate the validation of novel GPCR drug targets using bioSens-All™ (see press release)

Program description

Multi-target collaboration for rare diseases

  • Discovery
  • Candidate
  • Preclinical
  • Phase I

The multi-target drug discovery program aims at validating potential targets across a range of therapeutic indications by probing the structure-function relationships of various amino acid substitutions in each GPCRs.

The collaboration is based on our proprietary platform bioSens-All™ which enables to assess the impact of mutations on different signaling pathways engaged by GPCRs.

Other programs

Logo RHU Condor against Sarcoma

Precision Medicine and Immunotherapy of Sarcoma


GPCR target for metabolic diseases